Stocks and Investing Stocks and Investing
Fri, March 4, 2022

Mani Foroohar Maintained (BBIO) at Buy with Increased Target to $25 on, Mar 4th, 2022


Published on 2024-10-27 19:57:24 - WOPRAI, Mani Foroohar
  Print publication without navigation


Mani Foroohar of SVB Leerink, Maintained "BridgeBio Pharma, Inc." (BBIO) at Buy with Increased Target from $24 to $25 on, Mar 4th, 2022.

Mani has made no other calls on BBIO in the last 4 months.



There is 1 other peer that has a rating on BBIO. Out of the 1 peers that are also analyzing BBIO, 0 agree with Mani's Rating of Hold.



This is the rating of the analyst that currently disagrees with Mani


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $24 on, Tuesday, December 28th, 2021
Contributing Sources